Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 40.43 USD -1.13% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
Veracyte Inc?
Write Note

Veracyte Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Veracyte Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Veracyte Inc
NASDAQ:VCYT
Stock-Based Compensation
$34.1m
CAGR 3-Years
21%
CAGR 5-Years
32%
CAGR 10-Years
28%
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Veracyte Inc
Glance View

Market Cap
3.1B USD
Industry
Biotechnology

Veracyte Inc., founded in 2008, operates at the intriguing intersection of biotechnology and diagnostics, leveraging genomic insights to transform the landscape of disease diagnosis. The company's core mission is to improve the accuracy and efficiency of diagnostic testing, thus enabling better treatment decisions. Veracyte has woven innovation into its business model, creating a suite of genomic tests primarily for oncology and pulmonology. These tests are designed to resolve diagnostic ambiguity, particularly in cases where traditional tests might fall short. By harnessing advanced genomic technology, Veracyte empowers healthcare providers with definitive answers, thus facilitating timely and appropriate patient management. The company's revenue engine is driven by its extensive portfolio of products and services. At the heart of its operations is a series of diagnostic tests—such as Afirma for thyroid cancer, Percepta for lung cancer, and Envisia for idiopathic pulmonary fibrosis—each of which addresses key unmet medical needs. Veracyte generates income by selling these tests primarily to hospitals and healthcare providers, who in turn utilize the insights to bolster their clinical decision-making. Additionally, the company licenses its proprietary biobank and genomic platform to partners in research and pharma industries, unlocking further monetary streams. As payers increasingly recognize and reimburse the value of these precision diagnostic tools, Veracyte continues to strategically expand its market reach, reinforcing its role as a vital player in the biotech domain.

VCYT Intrinsic Value
17.39 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Veracyte Inc's Stock-Based Compensation?
Stock-Based Compensation
34.1m USD

Based on the financial report for Sep 30, 2024, Veracyte Inc's Stock-Based Compensation amounts to 34.1m USD.

What is Veracyte Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
28%

Over the last year, the Stock-Based Compensation growth was 5%. The average annual Stock-Based Compensation growth rates for Veracyte Inc have been 21% over the past three years , 32% over the past five years , and 28% over the past ten years .

Back to Top